KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1537.00
-¥23.00(-1.53%)
At close: 4:00 PM EST
¥1537.00
-¥23.00(-1.53%)
Day’s Range― - ―
52-Week Range¥1,123.00 - ¥1,725.00
Previous CloseN/A
Volume61.80K
Average Volume (3M)127.03K
Market Cap
¥63.06B
Enterprise Value¥84.71B
Total Cash (Recent Filing)¥16.62B
Total Debt (Recent Filing)¥26.48B
Price to Earnings (P/E)19.0
Beta0.52
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)179.30
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)77.6
Revenue Forecast (FY)¥125.58B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and steady equity growth provide durable financial flexibility. This supports sustained R&D investment, withstands pricing/reimbursement shocks in Japan’s healthcare system, and preserves capacity for opportunistic M&A or shareholder distributions over the medium term.
Improved Operating Cash GenerationA recovery to positive operating and free cash flow strengthens the company’s ability to self-fund development and commercialization. Sustained cash generation reduces reliance on external financing and supports long-term investment in pipeline and commercial scale-up.
Stable Multi‑year Revenue BaseA generally stable revenue base across recent years, anchored in focused therapeutic areas (respiratory, infectious, immunology), provides recurring demand and predictable sales channels. That structural stability underpins long-term cash flow and product lifecycle planning.
Bears Say
Sharp Margin CompressionMaterial margin deterioration erodes durable profitability and weakens return dynamics. Lower gross and net margins reduce reinvestment capacity and heighten sensitivity to pricing or cost inflation, making earnings recovery harder without structural cost or mix improvements.
Volatile Free Cash Flow HistorySwinging free cash flow complicates multi‑year planning and increases financing risk for R&D and commercialization. Inconsistent cash conversion signals exposure to working-capital swings or lumpy investments, reducing confidence in sustaining dividends or funding pipeline without external support.
Recent Revenue Decline And SensitivityA near-term revenue decline coupled with reported sensitivity to mix and costs indicates structural exposure to demand or pricing shifts. This raises the risk that further small volume or pricing headwinds will meaningfully pressure margins and earnings over the medium term.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1123.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥63.06B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on May 12, 2026. The company reported -¥11.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.68.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥37 which represents an annual dividend yield of 3.36%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of -¥11.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.259%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---